ScoreWhy is Indo US Bio-Tech Ltd ?
1
High Management Efficiency with a high ROCE of 27.98%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.91 times
3
Healthy long term growth as Net Sales has grown by an annual rate of 31.50%
4
Flat results in Sep 25
- PAT(Q) At Rs 3.45 cr has Fallen at -22.4% (vs previous 4Q average)
- PBDIT(Q) Lowest at Rs 4.17 cr.
- OPERATING PROFIT TO NET SALES (Q) Lowest at 13.52%
5
With ROCE of 16.4, it has a Attractive valuation with a 2.6 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -56.06%, its profits have risen by 43.9% ; the PEG ratio of the company is 0.4
6
Majority shareholders : Promoters
7
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 2.34% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -56.06% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Other Agricultural Products)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Indo US Bio-Tech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Indo US Bio-Tech
-41.57%
-0.85
65.71%
Sensex
8.49%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
25.18%
EBIT Growth (5y)
19.07%
EBIT to Interest (avg)
8.91
Debt to EBITDA (avg)
2.09
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.99
Tax Ratio
3.83%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.91%
ROE (avg)
30.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
17
Industry P/E
31
Price to Book Value
2.93
EV to EBIT
16.36
EV to EBITDA
15.30
EV to Capital Employed
2.47
EV to Sales
2.38
PEG Ratio
1.30
Dividend Yield
NA
ROCE (Latest)
16.37%
ROE (Latest)
17.11%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-9What is not working for the Company
PAT(Latest six months)
At Rs 6.45 cr has Grown at -31.46%
NET SALES(Q)
Lowest at Rs 22.80 cr
PBDIT(Q)
Lowest at Rs 4.15 cr.
PBT LESS OI(Q)
Lowest at Rs 3.15 cr.
EPS(Q)
Lowest at Rs 1.50
Loading Valuation Snapshot...
Here's what is not working for Indo US Bio-Tech
Net Sales - Quarterly
At Rs 22.80 cr has Fallen at -23.1% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 29.64 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
At Rs 6.45 cr has Grown at -31.46%
Year on Year (YoY)MOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
Net Sales - Quarterly
Lowest at Rs 22.80 cr
in the last five quartersMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Lowest at Rs 4.15 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 3.15 cr.
in the last five quartersMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
Earnings per Share (EPS) - Quarterly
Lowest at Rs 1.50
in the last five quartersMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (Rs)
